Portfolio Cockpit

v0.2

Non-opioid pain target landscape · Last refresh today, 09:14 · Owner M. Reyes · Weekly review cadence

AI Analyst Summary

Updated today

Two targets require review. NaV1.7 moved after new genetic evidence; NaV1.9 remains early but improving. Suggested next action: open the NaV1.7 workspace.

Open NaV1.7 workspace View evidence updates Generate brief

Target landscape map

Evidence confidence × development readiness · illustrative

anchor

candidate

watchlist

NaV1.8

NaV1.7

Review recommended

NaV1.9

TRPA1

P2X3

NGF

Evidence confidence →

Development readiness →

Target landscape6 of 6

Click a row to open the workspace

Target	Role	Conviction	Trend	Key driver	Modality	Owner	Review	Actions
NaV1.8 SCN10A · Public class update pending verification	Anchor	High	Stable	JOURNAVX commercial reference; Latigo Fast Track	Small molecule	CICompetitive Intelligence Updated 2d ago	Watchlist
NaV1.7 SCN9A · Isoform selectivity vs NaV1.5 / NaV1.4	Candidate	Moderate-High	Improving	New GWAS replication at SCN9A	Small molecule	TSTranslational Science Updated 3d ago	Review recommended	Open
NaV1.9 SCN11A · Limited tractability data	Candidate	Moderate	Improving	GWAS signal at SCN11A locus	Small molecule	TSTranslational Science Updated 3d ago	Review recommended
TRPA1 TRPA1 · Translation across pain phenotypes	Candidate	Moderate	Stable	Lilly LY3526318 POC published	Small molecule	PSPortfolio Strategy Updated 1w ago	Current
P2X3 P2RX3 · Pain-specific evidence limited	Candidate	Moderate	Stable	Class progress in chronic cough	Small molecule	CFClinical Feasibility Updated 3w ago	Current
NGF NGFB · No new resolution data published	Watchlist	Low	Stable	Class safety signals under review	Antibody (historically)	CICompetitive Intelligence Updated —	Needs source check

Coverage: six publicly active peripheral pain biology targets. ASIC3, sigma-1, CGRP-receptor not included in this view.